ReNerve (ASX: RNV) received an additional AU$139,537 in research and development tax incentives following an assessment of the company's overseas research activities, bringing its total refund to AU$516,606, according to a Friday filing with the Australian bourse.
The company said it is working and developing products aimed to provide a complete range of products for peripheral nerve repair and replacement.
The company's shares were down almost 4% in recent Friday trade, earlier hitting an all-time low.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。